Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody and a potent Notch pathway inhibitor, demonstrating efficacy in various cancer models both as a monotherapy and in conjunction with chemotherapy agents.
Molecular Weight:
145.65 (kDa)
CAS Number:
[1243262-17-0]
Target:
Gamma-secretase
* VAT and and shipping costs not included. Errors and price changes excepted